Cytokinetics Receives Orphan Drug Status for ALS Treatment
Promising data from a Phase I clinical trial of CK-2017357 was announced in January.
Promising data from a Phase I clinical trial of CK-2017357 was announced in January.
Strategic Medicine (SMI) specializes in patient and disease stratification with the end goals of providing better healthcare and identifying unmet clinical needs.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
Neomatrix of Irvine, Calif., has developed a fully automated, non-invasive device to assess a patient’s risk of developing breast cancer.
The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.
MicroTransponder is developing a wireless neurostimulation device for the treatment of chronic pain.
Sword Diagnostics of Illinois has developed a “next-generation” system to increase the sensitivity (and therefore accuracy) of diagnostic tests.
There’s one change that women don’t always discuss with their gynecologists.
Jaleva’s Stayzon technology utilizes a specific formulation of resins that is designed to keep medication in place for up to 96 hours and provide extended-release drug delivery to the skin.
LAMP (Lysosome-Associated Membrane Protein) is a gene that has been shown to enhance immune response when incorporated into a DNA vaccine.
Copyright © 2025 | WordPress Theme by MH Themes